title: Translational medicine lessons from flurizan's failure in Alzheimer's disease (AD) trial: Implication for future drug discovery and development for AD.
authors.affiliation: Department of Clinical Translational Medicine, Wyeth Research, Collegeville, Pennsylvania, USA. wanhi@wyeth.com <wanhi@wyeth.com>
authors.forename: Hong I
authors.initials: HI
authors.lastname: Wan
authors.forename: J Steve
authors.initials: JS
authors.lastname: Jacobsen
authors.forename: J Lynn
authors.initials: JL
authors.lastname: Rutkowski
authors.forename: Giora Z
authors.initials: GZ
authors.lastname: Feuerstein
mesh_terms: D000544:Alzheimer Disease / Q000188:drug therapy*; D000818:Animals; D015415:Biomarkers / Q000378:metabolism; D002986:Clinical Trials as Topic; D018450:Disease Progression; D055808:Drug Discovery; D005480:Flurbiprofen / Q000493:pharmacokinetics / Q000494:pharmacology / Q000627:therapeutic use*; D006801:Humans; D018579:Patient Selection; D015203:Reproducibility of Results; D057170:Translational Research, Biomedical; D017211:Treatment Failure
chemical_list: D015415:Biomarkers; C505522:tarenflurbil; D005480:Flurbiprofen